AR053312A1 - Derivados de guanidina triciclica como inhibdores de intercambio de proton de sodio, proceso de preparacion del compuesto, composicion farmaceutica y un proceso par su preparacion - Google Patents
Derivados de guanidina triciclica como inhibdores de intercambio de proton de sodio, proceso de preparacion del compuesto, composicion farmaceutica y un proceso par su preparacionInfo
- Publication number
- AR053312A1 AR053312A1 ARP050104717A ARP050104717A AR053312A1 AR 053312 A1 AR053312 A1 AR 053312A1 AR P050104717 A ARP050104717 A AR P050104717A AR P050104717 A ARP050104717 A AR P050104717A AR 053312 A1 AR053312 A1 AR 053312A1
- Authority
- AR
- Argentina
- Prior art keywords
- sulfonyl
- alkyl
- cycloalkyl
- substituted
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
- C07D327/06—Six-membered rings
- C07D327/08—[b,e]-condensed with two six-membered carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Se revelan derivados de guanidina que tienen un anillo tricíclico condensado. Estos derivados son inhibidores de intercambio de proton de sodio y resultan utiles como medicamentos para e tratamiento de, por ejemplo, desordenes de organos asociados con isquemia y reperfusion, arritmia cardíaca, hipertrofia cardíaca, hipertension, desordenes celulares proliferativos y diabetes. Reivindicacion 1: Un compuesto de la formula general (1) en donde: R1, R2, R3, R4, R5, R6, R7 y R8 son independiente entre sí seleccionados de: H, halogeno, hidroxi, hidroxialquilo, formilo, alcoxi, cicloalcoxi, ariloxi, alquiltio, alquilcarbonilo, carboxi, alquilcarboxilato, alquilo, alquenilo, cicloalquilo, arilo, ariloxicarbonilo, alquilaminoalquilo, aminocarbonilo, ciano, nitro, amidino, cloruro de sulfonilo, hidrazido de sulfonilo, alquilsulfonil, heterociclilsulfonilo, heteroarilsulfonilo, sulfonamida, alquil-NH-SO2-, cicloalquilo-NH-SO2, heterociclil-NH-SO2-, heteroaril-NH-SO2-, heteroaril- alquil-NH-SO2-, arilalquilo, heterociclilo, heteroarilo, guanidino carbonilo, guanidino, -NR'Rö y N=R'ö; R' y Rö son independiente entre sí y se seleccionan de: H, alquilo, cicloalquilo, arilo, arilalquilo, haloalquilo, tooalquilo, hidroxialquilo, alcoxialquilo,. Ariloxialquilo, carboxialquilo, aminoalquilo, mono- o di-alquil-aminoalquilo sustituido, cicloalquil-aminoalquilo, arilalquilaminoalquilo, alcoxiarilalquilo aminoalquilo, heterociclilalquilo, heterociclilaminoalquilo, heterociclilalquilaminoalquilo, heterociclilalquil-N[(alquil)]-alquilo, heteroarilalquilo, heteroarilalquilaminoalquilo, alcoxiarilalquilo-N[(alquil)]-alquilo, arilalquil-N[(alquil)]-alquilo, alcoxicarbonilo, cicloalquilcarbonilo, cicloalquilaminocarbonilo, arilcarbonilo, ariloxicarbonilo, aralcoxicarbonilo, heterociclilcarbonilo, CHO y alquilcarbonilo (donde dicho alquilo está no sustituido o sustituido por 1, 2 o 3 del mismo o diferentes sustituyentes seleccionados de: halo, hidroxi, alcoxi, alquilamino, cicloalquil amino, arilo y heterociclilo); R'ö se selecciona de: heterociclilo, cicloalquilo y alquilo; donde arilo está no sustituido o sustituido por 1 o 2 del mismo o de diferente grupos seleccionados de: nitro, alquilo, alcoxi, halogeno, haloalquilo, amino, mono- o dialquilamino, heterociclilalquilaminoalquilo, heteroarilo está no sustituido o sustituido por 1 o 2 del mismo o de diferente grupo seleccionado de: halogeno, nitro, amino, alquilamino, alquilo, alcoxi y alquilcarbonilo; heterociclilo está no sustituido o sustituido por 1 o 2 del mismo o de diferente grupo seleccionado de: alquilo, cicloalquilo, hidroxialquilo, alquilaminoalquilo, cicloalquilalquilo, cicloalquilcarbonilo heterociclilalquilo, heteroarilalquilo, heteroarilcarbonilo, arilalquilo, y oxo; guanidino y guanidinocarbonilo están no sustituido o sustituidos por 1, 2 o 3 del mismo o de diferente grupos seleccionados de: alquilo y alquilcarbonilo; con la salvedad de que por lo menos uno de entre R1, R2, R3, R4, R5, R6, R7 o R8 es guanidino o guanidinocarbonilo; U es C(O), CRaRb, O, NRa, o S(O)m; V es CRaRb o NRa; W es S(O)m; en donde, Ra es H, alquilo, cicloalquil, alquenilo o arilalquilo; Rb es H, alquilo, OH, ORa o OCORa; y m es el entero 0, 1 o 2; en todas sus formas estereoisoméricas y tautoméricas y mezclas de los mismos en todos los índices, y sus sales farmacéuticamente aceptables, solvatos farmacéuticamente aceptables, polimorfos y prodrogas farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1225MU2004 | 2004-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053312A1 true AR053312A1 (es) | 2007-05-02 |
Family
ID=38006671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104717A AR053312A1 (es) | 2004-11-10 | 2005-11-11 | Derivados de guanidina triciclica como inhibdores de intercambio de proton de sodio, proceso de preparacion del compuesto, composicion farmaceutica y un proceso par su preparacion |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7834001B2 (es) |
| EP (1) | EP1812420A1 (es) |
| JP (1) | JP4921375B2 (es) |
| KR (1) | KR20070106980A (es) |
| CN (2) | CN101076526A (es) |
| AR (1) | AR053312A1 (es) |
| AU (1) | AU2005303409B2 (es) |
| BR (1) | BRPI0516704A (es) |
| CA (1) | CA2587620A1 (es) |
| IL (1) | IL183086A0 (es) |
| MX (1) | MX2007005469A (es) |
| NZ (1) | NZ554936A (es) |
| RU (1) | RU2390521C2 (es) |
| TW (1) | TW200614995A (es) |
| WO (1) | WO2006051476A1 (es) |
| ZA (1) | ZA200703756B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200615273A (en) * | 2004-11-10 | 2006-05-16 | Nicholas Piramal India Ltd | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha |
| JP5773874B2 (ja) * | 2008-10-08 | 2015-09-02 | セファロン、インク． | ベンダムスチンの調製方法 |
| WO2012105588A1 (ja) * | 2011-02-02 | 2012-08-09 | アステラス製薬株式会社 | テトラヒドロイソキノリン誘導体 |
| RU2558087C2 (ru) * | 2013-10-22 | 2015-07-27 | Сергей Владимирович Шумилин | Способ управления нефтегазовым месторождением |
| RU2558088C2 (ru) * | 2013-10-23 | 2015-07-27 | Сергей Владимирович Шумилин | Способ управления нефтегазовой скважиной |
| EP3587391A1 (en) | 2018-06-22 | 2020-01-01 | Basf Se | Process for preparing nitrobenzyl bromides |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2094790B (en) * | 1981-03-13 | 1985-10-09 | Spofa Vereinigte Pharma Werke | Tricycle compounds |
| US5036067A (en) | 1990-03-14 | 1991-07-30 | Merck & Co., Inc. | Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase |
| EP0589336B1 (de) | 1992-09-22 | 1997-01-08 | Hoechst Aktiengesellschaft | Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika |
| DE4437874A1 (de) | 1994-10-22 | 1996-04-25 | Merck Patent Gmbh | Alkyl-5-methylsulfonyl-benzoylguanidin-Derivate |
| DE19542306A1 (de) * | 1995-11-14 | 1997-05-15 | Hoechst Ag | Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19548708A1 (de) | 1995-12-23 | 1997-06-26 | Merck Patent Gmbh | Cyclische Sulfone |
| DE19621483A1 (de) * | 1996-05-29 | 1997-12-04 | Hoechst Ag | Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| JPH10152481A (ja) * | 1996-09-25 | 1998-06-09 | Kanebo Ltd | ベンゾ［１，４］チアジン誘導体およびそれからなる医薬 |
| FR2765580B1 (fr) | 1997-07-01 | 1999-08-06 | Synthelabo | Derives de (1h-imidazol-4-yl)piperidine, leur preparation et leur application en therapeutique |
| AU4360200A (en) * | 1999-04-23 | 2000-11-10 | Bristol-Myers Squibb Company | Bicyclic acyl guanidine sodium/proton exchange inhibitors and method |
| DE10204989A1 (de) | 2002-02-07 | 2003-08-21 | Aventis Pharma Gmbh | Dihydro-thia-phenanthren-carbonyl-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
-
2005
- 2005-10-31 TW TW094138178A patent/TW200614995A/zh unknown
- 2005-11-08 NZ NZ554936A patent/NZ554936A/en not_active IP Right Cessation
- 2005-11-08 AU AU2005303409A patent/AU2005303409B2/en not_active Ceased
- 2005-11-08 BR BRPI0516704-3A patent/BRPI0516704A/pt not_active IP Right Cessation
- 2005-11-08 CA CA002587620A patent/CA2587620A1/en not_active Abandoned
- 2005-11-08 CN CNA2005800424281A patent/CN101076526A/zh active Pending
- 2005-11-08 EP EP05801218A patent/EP1812420A1/en not_active Withdrawn
- 2005-11-08 MX MX2007005469A patent/MX2007005469A/es active IP Right Grant
- 2005-11-08 WO PCT/IB2005/053653 patent/WO2006051476A1/en active Application Filing
- 2005-11-08 US US11/667,583 patent/US7834001B2/en not_active Expired - Fee Related
- 2005-11-08 KR KR1020077012882A patent/KR20070106980A/ko not_active Application Discontinuation
- 2005-11-08 CN CN2012104073981A patent/CN102952112A/zh active Pending
- 2005-11-08 JP JP2007540781A patent/JP4921375B2/ja not_active Expired - Fee Related
- 2005-11-08 RU RU2007121681/04A patent/RU2390521C2/ru not_active IP Right Cessation
- 2005-11-11 AR ARP050104717A patent/AR053312A1/es not_active Application Discontinuation
-
2007
- 2007-05-09 ZA ZA200703756A patent/ZA200703756B/en unknown
- 2007-05-09 IL IL183086A patent/IL183086A0/en unknown
-
2010
- 2010-06-30 US US12/827,277 patent/US8183234B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1812420A1 (en) | 2007-08-01 |
| JP2008519823A (ja) | 2008-06-12 |
| RU2007121681A (ru) | 2008-12-20 |
| IL183086A0 (en) | 2007-09-20 |
| TW200614995A (en) | 2006-05-16 |
| US20100267690A1 (en) | 2010-10-21 |
| US8183234B2 (en) | 2012-05-22 |
| RU2390521C2 (ru) | 2010-05-27 |
| JP4921375B2 (ja) | 2012-04-25 |
| CN102952112A (zh) | 2013-03-06 |
| ZA200703756B (en) | 2008-06-25 |
| KR20070106980A (ko) | 2007-11-06 |
| AU2005303409B2 (en) | 2011-12-15 |
| AU2005303409A1 (en) | 2006-05-18 |
| NZ554936A (en) | 2010-09-30 |
| MX2007005469A (es) | 2007-07-10 |
| CA2587620A1 (en) | 2006-05-18 |
| CN101076526A (zh) | 2007-11-21 |
| US20070299051A1 (en) | 2007-12-27 |
| WO2006051476A1 (en) | 2006-05-18 |
| BRPI0516704A (pt) | 2008-09-16 |
| US7834001B2 (en) | 2010-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053312A1 (es) | Derivados de guanidina triciclica como inhibdores de intercambio de proton de sodio, proceso de preparacion del compuesto, composicion farmaceutica y un proceso par su preparacion | |
| CO5200848A1 (es) | Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales | |
| BRPI0408704A (pt) | benzil-piridazinonas como inibidores de transcriptase reversa | |
| AR059961A1 (es) | Compuesto derivado de fenil tetrahidro-indazol, composiciones farmaceuticas que lo comprenden, usos para preparar un medicamento para el tratamiento de una enfermedad mediada por una reduccion o desequilibrio en la funcion del receptor de glutamato y procesos para su preparacion | |
| PE20220905A1 (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
| UY28135A1 (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
| JP2015143283A5 (es) | ||
| AR049706A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| AR056838A1 (es) | Derivados de 1,2,5-tiadiazol | |
| AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
| BRPI0408767B8 (pt) | inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica | |
| JP2011506438A5 (es) | ||
| UY27333A1 (es) | Nucleótidos 4` sustituidos | |
| UY28692A1 (es) | Nuevos derivados de quinolina | |
| CO4810375A1 (es) | Derivados de 9-amino-3-ceto eritromicina | |
| AR055616A1 (es) | Compuestos de tiofeno bencimidazol | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR059032A1 (es) | Combinacion de derivados de triazina y sensibilizadores de insulina | |
| DE602005018972D1 (de) | 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren | |
| CY1108632T1 (el) | Παραγωγα της 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline για θεραπεια της στειροτητας | |
| HRP20080119T5 (en) | Benzothiadiazine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| UY29739A1 (es) | Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones | |
| AR034585A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
| AR037459A1 (es) | Antagonistas vi del receptor ccr-3 | |
| AR029913A1 (es) | Un compuesto derivado de p-(sulfonil)-aril y -heteroaril amina, su uso, y una composicion farmaceutica que lo comprende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |